Active broad-market exchange-traded funds in Monday's regular session:
SPDR S&P 500 ( SPY ): +0.87%
iShares MSCI Emerging Markets Index ( EEM ): +0.86%
PowerShares QQQ Trust, Series ( QQQ ): +0.82%
iPath S&P 500 VIX ST Futures ETN ( VXX ): -3.47%
iShares Russell 2000 Index ( IWM ): +1.51%
Broad Market Indicators
Broad-market exchange-traded funds, including SPY, IWM and IVV were mixed. Actively traded PowerShares QQQ ( QQQ ) was up 0.18%.
U.S. stock futures are pointing to a higher open, with investors eyeing upcoming housing data for further direction on the health of the economy. U.S. housing starts are expected to have increased at a 965,000 annual pace in July, while separate data may show the consumer price index slowed in July, advancing 0.1 percent from 0.3 percent in June. Among stocks Home Depot (HD) gained more than 3% after the company raised its full-year guidance, while Elizabeth Arden tanked 15% after a huge Q2 miss.
Power Play: Consumer
Consumer Staples Select Sector SPDR (XLP), iShares Dow Jones US Consumer Goods (IYK), and Vanguard Consumer Staples ETF (VDC) were firmer.
Beauty-products company Elizabeth Arden (RDEN) reported Tuesday it swung to a fiscal Q4 adjusted loss that was far larger than the one analysts expected as revenue also missed the Street consensus and gross profit margin was halved, hurt by a steeper-than-anticipated drop in sales of celebrity fragrances. Excluding non-recurring costs, net of taxes, it had a loss of $1.04 per share in the latest quarter, compared with a year-earlier profit of $0.10 per diluted share. Analysts polled by Capital IQ were expecting a loss of $0.38 per share. The shares are down more than 15% pre-market.
Winners and Losers
Select Financial Sector SPDRs (XLF) was flat after gaining Monday. Direxion Daily Financial Bull 3X shares (FAS) was up 0.22% while its bearish counterpart, FAZ, was down 0.23%.
Bank of America (BAC) has named Thomas K. Montag as the company's sole COO, while co-COO David Darnell moves to Florida and becomes vice chairman. Darnell will continue overseeing global wealth and investment management, as well as business banking. Shares in the bank are slightly higher in pre-market trading .
Technology Select Sector SPDR ETF (XLK), iShares Dow Jones US Technology ETF (IYW), iShares S&P North American Technology ETF (IGM) and iShares S&P North American Technology-Software Index (IGV) were all unchanged after a higher close Monday. SPDR S&P International Technology Sector ETF (IPK) was also unchanged after a higher close.
Among semiconductor ETFs, SPDR S&P Semiconductor (XSD) and Semiconductor Sector Index Fund (SOXX) were also unchanged.
Yahoo Inc. (YHOO) is higher Monday amid several reports touting the company's upside potential despite the company's core business challenges.
In a positive technical note, Trade Ideas LLC regards YHOO as a momentum candidate, reported The Street. Such stocks are cited for historical back testing and price action which has lead to a positive trend in shares prior to a potential price decline. In addition,
Dow Jones U.S. Energy Fund (IYE) and Energy Select Sector SPDR (XLE) were unchanged after a higher close.
Crude was up 0.35%; United States Oil Fund (USO) was up 0.11%. Natural gas was up 1.4% and United States Natural Gas Fund (UNG) was up 1.39% and was one of the best-performing funds pre-market.
Gold was up 0.23%, while silver was up 0.25%. Among rare metal funds, SPDR Gold Trust (GLD) was up 0.2% and iShares Silver Trust (SLV) was inactive.
Health Care SPDR (XLV), iShares Dow Jones US Healthcare (IYH) and Vanguard Health Care ETF (VHT) were unchanged after a higher close Monday. Biotech ETF iShares NASDAQ Biotechnology Index (IBB) was up 0.18%.
Actavis (ACT) confirmed positive topline results from RECLAIM-1 and -2, pivotal Phase III studies evaluating the potential for the investigational antibiotic, ceftazidime-avibactam as a treatment for adult hospitalized patients with complicated intra-abdominal infections. Ceftazidime-avibactam consists of a cephalosporin, an established treatment for serious bacterial infections, and a next generation non-beta lactam beta-lactamase inhibitor.
The shares were edging higher pre-market.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.